Skip to main content
Lifecare ASA logo

Lifecare ASA — Investor Relations & Filings

Ticker · LIFE ISIN · NO0013355859 LEI · 254900D88MYGZ7JD5P39 OL Manufacturing
Open in API
Filings indexed 809 across all filing types
Latest filing 2025-05-30 Regulatory Filings
Country NO Norway
Listing OL LIFE

About Lifecare ASA

https://lifecare.no/

Lifecare ASA is a clinical-stage medical sensor company specializing in the development of nanotechnology for medical applications. Its core activity involves creating miniaturized, implantable, and long-term nanobiosensors for the continuous monitoring of various body analytes. The company's primary focus is on developing a sensor for correct and continuous glucose monitoring to improve diabetes management. The business model is based on developing and licensing its proprietary sensor technology to facilitate the production and sale of advanced medical devices.

Recent filings

Filing Released Lang Actions
Lifecare announces second clinical trial site at Pfützner Science & Health Institute in Mainz, Germany - Attachment: Lifecare announces second clinical trial site at Pfützner Science & Health Institut
Regulatory Filings Classification · 1% confidence The document is a press release dated May 30, 2025, announcing the selection of a second clinical trial site for Lifecare's CGM technology. It details operational updates, timelines for regulatory submissions and trials, and includes quotes from the CEO. This type of announcement, which communicates specific operational or clinical progress without being a full financial report (like 10-K or IR) or a formal regulatory filing like a Director's Dealing or Major Shareholding notification, fits best under the general category of Regulatory Filings (RNS) as a miscellaneous corporate announcement, or potentially a Legal Proceedings Report (LTR) if the context implied a regulatory action, but here it is purely operational news. Given the options, RNS serves as the best general category for non-standard, timely corporate news releases that aren't covered by more specific codes like DIV, ER, or MANG. It is not an AGM-R, 10-K, AR, CT, CAP, DVA, DLST, DIRS, ER, SR, XLSX, FS, CGR, IRAT, IR, IP, LTR (it's an announcement, not a report on proceedings), TAR, MRQ, MDA, NAV, DIV, PSI, DEF 14A, RPA (it is the news itself, not just announcing a report), SHA, or POS. Therefore, RNS is the most appropriate fallback.
2025-05-30 English
Lifecare announces second clinical trial site at Pfützner Science & Health Institute in Mainz, Germany
Regulatory Filings Classification · 1% confidence The document is a short announcement (3170 characters) dated May 30, 2025, detailing the selection of a second clinical trial site for Lifecare's CGM technology. It mentions previous regulatory submissions and appointments but does not contain the full financial results of a period (ruling out ER, IR, 10-K) nor is it a formal legal filing or management change announcement. Since it is a specific operational update that doesn't fit the defined categories like 'Capital/Financing Update' (CAP) or 'Legal Proceedings Report' (LTR), and it is not an announcement *about* a report (RPA), the most appropriate fallback category is 'Regulatory Filings' (RNS) for general corporate announcements that don't fit elsewhere.
2025-05-30 English
Lifecare appoints renowned metabolic expert Prof. Simon Dankel as Principal Investigator for upcoming clinical trial - Attachment: Lifecare appoints renowned metabolic expert Prof. Simon Dankel as Pri
Regulatory Filings Classification · 1% confidence The document announces a specific operational event: the appointment of Professor Simon Dankel as Principal Investigator for an upcoming clinical trial. This relates to management/personnel decisions concerning key operational roles, although it is not a change in the Board of Directors (MANG) or a general management announcement. It is a specific announcement regarding a key scientific/investigative role critical to the company's R&D progress. Given the provided definitions, this type of announcement—a significant operational/personnel appointment outside of the formal Board structure—does not fit neatly into the primary categories like ER, 10-K, or CT. It is closest to a general corporate announcement. Since it is not a director change (MANG), dividend (DIV), or financing event (CAP), and it is not a report publication announcement (RPA), the most appropriate fallback category is Regulatory Filings (RNS) for miscellaneous, non-standard corporate news that doesn't fit elsewhere, although it strongly signals operational progress.
2025-05-27 English
Lifecare appoints renowned metabolic expert Prof. Simon Dankel as Principal Investigator for upcoming clinical trial
Regulatory Filings Classification · 1% confidence The document is a press release dated May 27, 2025, announcing the appointment of a Principal Investigator (Prof. Simon Dankel) for an upcoming clinical trial related to the company's CGM technology. This type of announcement concerns management/personnel decisions related to research and development, but it is not a change in the Board of Directors or senior management (MANG). It is also not a standard financial release (ER, IR) or a regulatory filing itself. Since it announces a key operational/personnel decision that impacts the company's direction and execution, and it doesn't fit the specific categories like DIRS, DIV, or CAP, it falls best under the general category for significant corporate announcements that are not strictly financial or regulatory filings. Given the options, this is a significant corporate update. It is closest to an announcement regarding management/operational structure, but since 'MANG' is strictly defined as Board/Senior Management changes, and there is no specific category for clinical trial personnel appointments, the most appropriate fallback category for a non-standard, material corporate announcement is 'RNS' (Regulatory Filings/General Regulatory Announcements). The document length is short (2443 chars), but it is the primary content, not an announcement *of* another document.
2025-05-27 English
Lifecare files for human clinical trial, paving the way for CE-mark
Regulatory Filings Classification · 1% confidence The document is a press release dated May 20, 2025, announcing that Lifecare ASA has filed for regulatory approval to initiate a human clinical trial for its Continuous Glucose Monitoring (CGM) implant. It discusses regulatory milestones, expected timelines for trials, and future commercial plans. This type of announcement, detailing progress on product development, regulatory submissions, and strategic milestones, does not fit neatly into the specific financial reporting categories (like 10-K, ER, IR) or specific corporate actions (like DIV, DIRS, M&A). It is a general corporate update related to product development and regulatory progress. Since it is not a specific financial report, a management discussion, or a defined corporate action like a dividend or share issue, the most appropriate classification is the general regulatory announcement fallback category, RNS (Regulatory Filings). The document length is short (2115 chars), but it is the primary content, not an announcement *of* another report.
2025-05-20 English
Lifecare files for human clinical trial, paving the way for CE-mark
Regulatory Filings Classification · 1% confidence The document is a short press release announcing that Lifecare ASA has filed for regulatory approval to initiate a human clinical trial for its CGM implant. It discusses regulatory milestones (CE-mark trial, expected approval in Q3 2025) and strategic progress. It is not a full financial report (10-K, IR, ER), a management change announcement (MANG), or a director's dealing report (DIRS). Since it is a specific announcement regarding regulatory progress and strategic milestones that doesn't fit the other specific categories like M&A (TAR) or Capital (CAP), and it is not a general report publication announcement (RPA) but rather the substance of a regulatory step, it best fits the general 'Regulatory Filings' category (RNS) as a miscellaneous regulatory/operational update, or potentially 'LTR' if the filing itself is considered a legal/regulatory action. Given the context of a standard operational update about a regulatory submission, RNS is the most appropriate fallback for non-financial, non-governance specific announcements.
2025-05-20 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.